◎ Sugi Atlas

Atlas / Drug / Abemaciclib

Abemaciclib

drug
On this page

Also known as Ly-2835219LY2835219VerzenioVerzeniosLY2835219 FREE BASECDK4/6 DUAL INHIBITORABEMACICLIB (LY2835219)AmebaciclibAbemacicilibAbemaciclibAbemiciclibAbemacidib

Summary

Abemaciclib (CHEMBL3301610) is an approved small molecule (ATC L01EF03) targeting CDK4 and CDK6; indicated across 53 conditions including neoplasm and breast carcinoma; with CIViC clinical evidence for 5 variant-indication associations (e.g. KRAS Mutation in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EF03
  • Targets: 2 (CDK4, CDK6)
  • Indications: 53 conditions
  • Clinical trials: 214
  • Precision-oncology evidence (CIViC): 5 variant–indication associations
  • Chemistry: 506.6 Da · C27H32F2N8

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3301610
NameAbemaciclib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID46220502
ATCL01EF03
Molecular formulaC27H32F2N8
Molecular weight506.6
InChIKeyUZWDCWONPYILKI-UHFFFAOYSA-N

SMILES: CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F

IUPAC name: N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine

Also known as: Abemaciclib, Ly-2835219, LY-2835219, LY2835219, Verzenio, Verzenios, ABEMACICLIB, LY2835219 FREE BASE, VERZENIOS, VERZENIO, CDK4/6 DUAL INHIBITOR, ABEMACICLIB (LY2835219)

Parent form; salt/anhydrous children: CHEMBL4290012, CHEMBL4474565, CHEMBL4534140, CHEMBL4560869

Patent coverage: 3,076 distinct patent families (7,045 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 6,506 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CDK4cyclin dependent kinase 4Inhibition8.758%P11802
CDK6cyclin dependent kinase 6Inhibition852.1%Q00534

Broader ChEMBL bioactivity targets: 81 (assay-derived). Sample: Dual specificity tyrosine-phosphorylation-regulated kinase 4, Serine/threonine-protein kinase ICK, 5-hydroxytryptamine receptor 2B, Cyclin-dependent kinase 5/CDK5 activator 1, Cyclin-dependent kinase 4/cyclin D1, Cyclin-dependent kinase 1/cyclin B1, Cyclin-dependent kinase 2/cyclin E1, Receptor-type tyrosine-protein kinase FLT3, Epidermal growth factor receptor, Cyclin-dependent kinase 7/ cyclin H.

Bioactivity

ChEMBL activities: 233 potent at pChembl ≥ 5 of 242 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
CDK49.59IC500.26nMCHEMBL_ACT_28711613
CDK49.59IC500.26nMCHEMBL_ACT_28711757
CCND19.37IC500.43nMCHEMBL_ACT_26333769
CDK49.34IC500.46nMCHEMBL_ACT_26333766
CDK49.22Ki0.6nMCHEMBL_ACT_15678963
CDK49.22Ki0.6nMCHEMBL_ACT_26281853
CDK49.22IC500.6nMCHEMBL_ACT_26333810
CLK19.07Kd0.85nMCHEMBL_ACT_25065199
CDK48.97IC501.07nMCHEMBL_ACT_25993914
CCND18.9IC501.26nMCHEMBL_ACT_25993926
CDK48.82IC501.5nMCHEMBL_ACT_24919604
CDK48.77IC501.7nMCHEMBL_ACT_18497289
CDK48.74IC501.82nMCHEMBL_ACT_18851156
CDK48.74IC501.8nMCHEMBL_ACT_22960037
CDK68.72IC501.9nMCHEMBL_ACT_18460833
CDK48.72IC501.9nMCHEMBL_ACT_18460853
CDK48.7IC502nMCHEMBL_ACT_15678959
CDK48.7Ki2nMCHEMBL_ACT_16737206
CDK48.7IC502nMCHEMBL_ACT_18497272
CDK48.7IC502nMCHEMBL_ACT_18538678
CDK48.7IC502nMCHEMBL_ACT_18784864
CDK48.7IC502nMCHEMBL_ACT_19027214
CDK48.7IC502nMCHEMBL_ACT_20641497
CDK48.7IC502nMCHEMBL_ACT_24958875
CDK48.7IC502nMCHEMBL_ACT_24984404
CDK48.7IC502nMCHEMBL_ACT_26214033
CDK48.7IC502nMCHEMBL_ACT_26281850
CDK48.7IC502nMCHEMBL_ACT_28471460
CDK48.7IC502nMCHEMBL_ACT_28471535
CDK48.7IC502nMCHEMBL_ACT_29144567

Target pathways

Aggregated over 2 target gene(s): CDK4, CDK6.

Top Reactome pathways

52 total, by targets touching each:

PathwayTargetsGenes
Cell Cycle2CDK4, CDK6
Disease2CDK4, CDK6
Generic Transcription Pathway2CDK4, CDK6
Cellular responses to stress2CDK4, CDK6
Oxidative Stress Induced Senescence2CDK4, CDK6
Senescence-Associated Secretory Phenotype (SASP)2CDK4, CDK6
Cellular Senescence2CDK4, CDK6
Oncogene Induced Senescence2CDK4, CDK6
Mitotic G1 phase and G1/S transition2CDK4, CDK6
Cyclin D associated events in G12CDK4, CDK6
G1 Phase2CDK4, CDK6
Cell Cycle, Mitotic2CDK4, CDK6
RNA Polymerase II Transcription2CDK4, CDK6
Gene expression (Transcription)2CDK4, CDK6
Cellular responses to stimuli2CDK4, CDK6
Diseases of Cellular Senescence2CDK4, CDK6
Evasion of Oncogene Induced Senescence Due to p16INK4A Defects2CDK4, CDK6
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK62CDK4, CDK6
Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects2CDK4, CDK6
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK62CDK4, CDK6
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects2CDK4, CDK6
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)2CDK4, CDK6
Diseases of mitotic cell cycle2CDK4, CDK6
Diseases of cellular response to stress2CDK4, CDK6
Aberrant regulation of mitotic cell cycle due to RB1 defects2CDK4, CDK6
Drug-mediated inhibition of CDK4/CDK6 activity2CDK4, CDK6
Developmental Biology1CDK4
Reproduction1CDK4
Meiosis1CDK4
Signal Transduction1CDK4

Dominant GO biological processes

GO termTargets
G1/S transition of mitotic cell cycle2
signal transduction2
regulation of G2/M transition of mitotic cell cycle2
regulation of gene expression2
positive regulation of fibroblast proliferation2
cell division2
regulation of cell cycle2
protein phosphorylation2
positive regulation of cell population proliferation1
response to xenobiotic stimulus1
positive regulation of G2/M transition of mitotic cell cycle1
regulation of transcription initiation by RNA polymerase II1
regulation of type B pancreatic cell proliferation1
cellular response to lipopolysaccharide1
cellular response to interleukin-41

Indications & clinical

Indications

53 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
breast carcinoma4MONDO:0004989EFO:0000305
breast neoplasm4MONDO:0021100EFO:0003869
HER2 positive breast carcinoma4MONDO:0006244EFO:1000294
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
dedifferentiated liposarcoma3MONDO:0020563EFO:0003085
mantle cell lymphoma2MONDO:0018876EFO:1001469
cutaneous melanoma2MONDO:0005012EFO:0000389
glioblastoma2MONDO:0018177EFO:0000519
mesothelioma2MONDO:0005065EFO:0000588
melanoma2MONDO:0005105EFO:0000756
brain neoplasm2MONDO:0021211EFO:0003833
upper aerodigestive tract neoplasm2MONDO:0005398EFO:0004284
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
hepatocellular carcinoma2MONDO:0007256EFO:0000182
female reproductive organ cancer2MONDO:0001416EFO:1001331
oligodendroglioma2MONDO:0016695EFO:0000632
endometrium neoplasm2MONDO:0021251MONDO:0011962
lung neoplasm2MONDO:0021117MONDO:0008903
angiosarcoma2MONDO:0016982EFO:0003968
male breast carcinoma2MONDO:0005628EFO:0006861
meningioma2MONDO:0016642MONDO:0016642
pancreatic neuroendocrine tumor2MONDO:0019954EFO:1000045
paraganglioma2MONDO:0000448EFO:1000453
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
lymphoma1MONDO:0005062EFO:0000574
Ewing sarcoma1MONDO:0012817EFO:0000174
neuroblastoma1MONDO:0005072EFO:0000621
osteosarcoma1MONDO:0009807EFO:0000637
rhabdomyosarcoma1MONDO:0005212EFO:0002918
rhabdoid tumor1MONDO:0002728EFO:0005701
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
plasma cell myeloma1MONDO:0009693EFO:0001378
diffuse intrinsic pontine glioma1MONDO:0006033EFO:1000026
clear cell renal carcinoma1MONDO:0005005EFO:0000349
Kaposi’s sarcoma1MONDO:0005055EFO:0000558
prostate adenocarcinoma1MONDO:0005082EFO:0000673
ovarian carcinoma1MONDO:0005140EFO:0001075
serous adenocarcinoma1MONDO:0005278EFO:0003825
neurofibromatosis type 11MONDO:0018975MONDO:0018975
metastatic prostate carcinoma1MONDO:0004956EFO:0000196
prostate carcinoma1MONDO:0005159EFO:0001663
renal cell adenocarcinoma1MONDO:0005549EFO:0005708
colorectal neoplasm1MONDO:0005335MONDO:0005575
glioma0MONDO:0021042MONDO:0100342

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 214.

Phase distribution

PhaseTrials
PHASE284
PHASE147
PHASE1/PHASE235
PHASE322
Not specified14
PHASE46
EARLY_PHASE15
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05362760PHASE4RECRUITINGCombination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
NCT06169371PHASE4RECRUITINGAbemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT03988114PHASE4WITHDRAWNA Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
NCT04031885PHASE4TERMINATEDA Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
NCT04707196PHASE4COMPLETEDA Study of Abemaciclib in Indian Women With Advanced Breast Cancer
NCT07487129PHASE4COMPLETEDClinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt
NCT02107703PHASE3ACTIVE_NOT_RECRUITINGA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02152631PHASE3ACTIVE_NOT_RECRUITINGA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02246621PHASE3ACTIVE_NOT_RECRUITINGA Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02763566PHASE3ACTIVE_NOT_RECRUITINGA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT03155997PHASE3ACTIVE_NOT_RECRUITINGEndocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03706365PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT04158362PHASE3ACTIVE_NOT_RECRUITINGEndocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
NCT04584853PHASE3ACTIVE_NOT_RECRUITINGPreOperative Endocrine Therapy for Individualised Care With Abemaciclib
NCT04862663PHASE3RECRUITINGCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04964934PHASE3ACTIVE_NOT_RECRUITINGPhase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04967521PHASE3ACTIVE_NOT_RECRUITINGSARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
NCT04975308PHASE3ACTIVE_NOT_RECRUITINGA Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT05169567PHASE3ACTIVE_NOT_RECRUITINGAbemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05288166PHASE3ACTIVE_NOT_RECRUITINGA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05891093PHASE3RECRUITINGEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05952557PHASE3RECRUITINGAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT06065748PHASE3RECRUITINGA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06380751PHASE3RECRUITINGSaruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06760637PHASE3ACTIVE_NOT_RECRUITINGStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT07174336PHASE3RECRUITINGA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07190443PHASE3RECRUITINGAdjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
NCT07492641PHASE3RECRUITINGBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT04752332PHASE3TERMINATEDA Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
NCT01042379PHASE2RECRUITINGI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT02523014PHASE2RECRUITINGVismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02693535PHASE2RECRUITINGTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02747004PHASE2ACTIVE_NOT_RECRUITINGA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
NCT02846987PHASE2ACTIVE_NOT_RECRUITINGStudy of Abemaciclib in Dedifferentiated Liposarcoma
NCT02925234PHASE2RECRUITINGThe Drug Rediscovery Protocol (DRUP Trial)
NCT02977780PHASE2RECRUITINGINdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02981940PHASE2ACTIVE_NOT_RECRUITINGA Study of Abemaciclib in Recurrent Glioblastoma
NCT03220646PHASE2ACTIVE_NOT_RECRUITINGAbemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
NCT03310879PHASE2RECRUITINGStudy of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
NCT03424005PHASE1/PHASE2RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Clinical evidence (CIViC)

Variant × indication × effect (5 predictive associations from 5 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
KRAS MutationLung Non-small Cell CarcinomaSensitivity/ResponseAbemaciclibCIViC BEID4842
KRAS A146VLung Non-small Cell CarcinomaSensitivity/ResponseAbemaciclibCIViC CEID794
SMARCA4 LossOvarian Small Cell CarcinomaSensitivity/ResponsePalbociclib + Ribociclib + AbemaciclibCIViC DEID7154
SMARCA4 LossLung Non-small Cell CarcinomaSensitivity/ResponsePalbociclib + AbemaciclibCIViC DEID7155
CDK6 AmplificationEstrogen-receptor Positive Breast CancerResistanceAbemaciclibCIViC DEID4843

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 4 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

63 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
DABRAFENIBChEMBLPhase 4 (approved)CDK4, CDK6
PALBOCICLIBChEMBLPhase 4 (approved)CDK4, CDK6
RIBOCICLIBChEMBLPhase 4 (approved)CDK4, CDK6
TRILACICLIBChEMBLPhase 4 (approved)CDK4, CDK6
ALVOCIDIBChEMBLPhase 3CDK4, CDK6
DALPICICLIBChEMBLPhase 3CDK4, CDK6
DINACICLIBChEMBLPhase 3CDK4, CDK6
DOVITINIBChEMBLPhase 3CDK4, CDK6
LEROCICLIBChEMBLPhase 3CDK4, CDK6
LESTAURTINIBChEMBLPhase 3CDK4, CDK6
QUERCETINChEMBLPhase 3CDK4, CDK6
AT-7519ChEMBLPhase 2CDK4, CDK6
AT-9283ChEMBLPhase 2CDK4, CDK6
ATIRMOCICLIBChEMBLPhase 2CDK4, CDK6
CROZBACICLIBChEMBLPhase 2CDK4, CDK6
CT-7001ChEMBLPhase 2CDK4, CDK6
CULMERCICLIBChEMBLPhase 2CDK4, CDK6
EBVACICLIBChEMBLPhase 2CDK4, CDK6
ECIRUCICLIBChEMBLPhase 2CDK4, CDK6
INDIRUBINChEMBLPhase 2CDK4, CDK6
INIXACICLIBChEMBLPhase 2CDK4, CDK6
ISTISOCICLIBChEMBLPhase 2CDK4, CDK6
MILCICLIBChEMBLPhase 2CDK4, CDK6
NARAZACICLIBChEMBLPhase 2CDK4, CDK6
RG-547ChEMBLPhase 2CDK4, CDK6
RIVICICLIBChEMBLPhase 2CDK4, CDK6
SELICICLIBChEMBLPhase 2CDK4, CDK6
TEGTOCICLIBChEMBLPhase 2CDK4, CDK6
ULECACICLIBChEMBLPhase 2CDK4, CDK6
VORUCICLIBChEMBLPhase 2CDK4, CDK6
ZEMIRCICLIBChEMBLPhase 2CDK4, CDK6
AfatinibPubChemApprovedCDK4, CDK6
BinimetinibPubChemApprovedCDK4, CDK6
CrizotinibPubChemApprovedCDK4, CDK6
dacomitinibPubChemApprovedCDK4, CDK6
FostamatinibPubChemApprovedCDK4, CDK6
GefitinibPubChemApprovedCDK4, CDK6
IdelalisibPubChemApprovedCDK4, CDK6
PazopanibPubChemApprovedCDK4, CDK6
PomalidomidePubChemApprovedCDK4, CDK6
regorafenibPubChemApprovedCDK4, CDK6
SelumetinibPubChemApprovedCDK4, CDK6
TrametinibPubChemApprovedCDK4, CDK6
CERITINIBChEMBLPhase 4 (approved)CDK4
ENCORAFENIBChEMBLPhase 4 (approved)CDK4
FEDRATINIBChEMBLPhase 4 (approved)CDK4
GILTERITINIBChEMBLPhase 4 (approved)CDK4
MOMELOTINIBChEMBLPhase 4 (approved)CDK6
NINTEDANIBChEMBLPhase 4 (approved)CDK4
OLAPARIBChEMBLPhase 4 (approved)CDK6
SORAFENIBChEMBLPhase 4 (approved)CDK6
SUNITINIBChEMBLPhase 4 (approved)CDK4
RUBOXISTAURINChEMBLPhase 3CDK4
BI-2536ChEMBLPhase 2CDK4
CYC-065ChEMBLPhase 2CDK4
ELLAGIC ACIDChEMBLPhase 2CDK4
FISETINChEMBLPhase 2CDK6
LY-2090314ChEMBLPhase 2CDK4
REBASTINIBChEMBLPhase 2CDK4
RONICICLIBChEMBLPhase 2CDK4

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot